title: Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review.
abstract: BACKGROUND
  In preclinical studies, the efficacy of the combination of antiangiogenic agents with chemotherapy seems to be dependent on the specific cytotoxic agent. We conducted a systematic review of the efficacy of bevacizumab in combination with taxane or non-taxane containing regimens for untreated, nonsquamous non-small-cell lung cancer patients.
  
  
  METHODS
  An extensive search of published clinical trials was conducted from electronic databases (MEDLINE, EMBASE, and Cochrane) and meeting proceedings using relevant search criteria. Phase 2 and randomized trials reporting on the efficacy of bevacizumab combined with taxane or non-taxane regimens were selected. A systematic analysis of extracted data was performed using Comprehensive Meta-Analysis (Version 2.2) software. Clinical outcome in patients treated with taxane versus non-taxane regimen was compared using point estimates for weighted values of median overall survival, progression-free survival, and response rate.
  
  
  RESULTS
  Twenty-nine studies reported between 2005 and 2015 were eligible. A total of 5890 patients (2767 and 3123 in the taxane and non-taxane groups, respectively) were included. The taxane and non-taxane groups were comparable in patient characteristics: median age, 62.8 versus 61.2 years; males, 57% versus 58%; adenocarcinomas, 83% versus 83%; stage IV, 87% versus 82%; performance status 0/1- 45/55% versus 41/59%, respectively. The weighted median overall survival was 14.4 versus 13.7 months (p = 0.5); progression-free survival was 6.93 versus 6.99 months (p = 0.61); response rate was 41% versus 39% (p = 0.65) for taxane and non-taxane groups.
  
  
  CONCLUSIONS
  The outcomes between taxane and non-taxane regimens when given in combination with bevacizumab for patients with nonsquamous non-small-cell lung cancer are comparable.
authors.affiliation: *Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia; †Winship Cancer Institute of Emory University, Atlanta, Georgia; ‡Biostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, California; §Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia; and ‖Penn State Hershey Cancer Institute, Hershey, Pennsylvania.
authors.forename: Madhusmita
authors.initials: M
authors.lastname: Behera
authors.forename: Rathi N
authors.initials: RN
authors.lastname: Pillai
authors.forename: Taofeek K
authors.initials: TK
authors.lastname: Owonikoko
authors.forename: Sungjin
authors.initials: S
authors.lastname: Kim
authors.forename: Conor
authors.initials: C
authors.lastname: Steuer
authors.forename: Zhengjia
authors.initials: Z
authors.lastname: Chen
authors.forename: Nabil F
authors.initials: NF
authors.lastname: Saba
authors.forename: Chandra P
authors.initials: CP
authors.lastname: Belani
authors.forename: Fadlo R
authors.initials: FR
authors.lastname: Khuri
authors.forename: Suresh S
authors.initials: SS
authors.lastname: Ramalingam
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D000077143:Docetaxel; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin